



QIAGEN MARSEILLE SUMMONED THE ITALIAN COMPANY AB ANALITICA S.R.L. BEFORE THE VENICE COURT

Marseille, May 6th, 2013 - QIAGEN Marseille, subsidiary of the QIAGEN Group, previously IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announces that the company summoned the Italian company AB Analitica S.r.l. before the Venice Court on 15 March 2013.

QIAGEN Marseille is the exclusive licensee of European Patent No. 1 692 281, which protects methods and kits for the diagnosis of Polycythemia Vera and other myeloproliferative syndromes through the detection of a mutation within the JAK2-V617F gene. This breakthrough technology has been licensed to QIAGEN Marseille, on a worldwide and exclusive basis, by the French Institut Gustave Roussy, the French National Health and Medical Research Institute (INSERM) and the Assistance Publique – Hôpitaux de Paris (AP-HP).

According to QIAGEN Marseille, AB Analitica's kits for the detection of the JAK2 mutation, which are known as GeneQuality JAK2, RealQuality RS-JAK2 V617F and RealQuality RS-JAK2 V617F Q, would infringe various claims of European Patent No. 1 692 281 exclusively licensed to QIAGEN Marseille. The plaintiff is therefore seeking, inter alia, a permanent injunction against AB Analitica and the recovery of the damages suffered as a consequence to the infringement. Although no decision has yet been issued on the merits of QIAGEN Marseille's claims vis à vis AB Analitica, this action follows a search order granted by the Venice Court, whereby QIAGEN Marseille has been able to collect relevant evidence at the premises of the defendant in Padua.

Vincent Fert, Chief Executive Officer of QIAGEN Marseille, stated: "*QIAGEN Marseille takes the protection of its IP rights (and particularly of this patent) very seriously. We will react against any act which we consider to be an infringement of one of our patents. We are confident that the case (which has of course just started) will allow QIAGEN Marseille to obtain the restoration of its exclusive rights on the technology for the detection of the JAK2 mutation*".

About QIAGEN Marseille

QIAGEN Marseille develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, QIAGEN Marseille is also developing diagnostic tools targeting other cancers. Its goal is to provide information, remaining unavailable until now, to sustain the development of personalized medicine.

Founded as IPSOGEN in 1999, the Company is, since July 2011, a subsidiary of the QIAGEN Group, the leading global provider of sample and assay technologies.

From January 1st 2013, IPSOGEN has changed its company name to QIAGEN Marseille. The Company, located in Marseille, France, employed 74 people as of December 31st, 2012.

Further information can be found at www.qiagenmarseille.com

Contacts :

QIAGEN Marseille

Vincent Fert
CEO
Tel : + 33 (0)4 91 29 30 90
vincent.fert@qiagen.com

Press relations
Marielle Bricman, ATCG Press
Mob. : + 33 (0)6 26 94 18 53
mb@atcg-partners.com

